Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CAMPATH-IH in multiple sclerosis

T Moreau1, A Coles, M Wing

  • 1University of Cambridge Neurology unit, Addenbrooke's Hospital.

Multiple Sclerosis (Houndmills, Basingstoke, England)
|July 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plasma cell depletion with bortezomib in the treatment of refractory N-methyl-d-aspartate (NMDA) receptor antibody encephalitis. Rational developments in neuroimmunological treatment.

European journal of neurology·2018
Same author

The role of the immune system in kidney disease.

Clinical and experimental immunology·2018
Same author

Evaluation of cardiovascular risk-lowering health benefits accruing from laboratory-based, community-based and exercise-referral exercise programmes.

BMJ open sport & exercise medicine·2016
Same author

Acting on incidental findings in research imaging.

BMJ (Clinical research ed.)·2015
Same author

Sample sizes for lesion magnetisation transfer ratio outcomes in remyelination trials for multiple sclerosis.

Multiple sclerosis and related disorders·2015
Same author

Exome sequencing in single cells from the cerebrospinal fluid in multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2014
Same journal

UK consensus on pregnancy in multiple sclerosis: An update to 'Association of British Neurologists' guidance.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Comparative effectiveness of rituximab versus ocrelizumab in relapsing multiple sclerosis on clinical relapses and radiological outcomes in British Columbia, Canada.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Invisible symptoms in multiple sclerosis and their impact on social role participation: A multidimensional analysis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Interaction between smoking and <i>HLA-A*02:01</i> in multiple sclerosis progression.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Impact of multiple sclerosis disease-modifying therapies on chronic lesion tissue expansion.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Tobacco smoking disrupts bile acid and tryptophan metabolism in multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
See all related articles

CAMPATH-IH treatment for multiple sclerosis (MS) reduced disease activity. However, antibody infusions caused temporary symptom flares, linked to cytokine release, which methylprednisolone could prevent.

Area of Science:

  • Immunology
  • Neurology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system.
  • CAMPATH-IH (alemtuzumab) targets CD52 on lymphocytes and monocytes, showing promise in MS treatment.
  • Understanding the mechanisms behind MS symptom exacerbation during immunotherapy is crucial.

Purpose of the Study:

  • To evaluate the efficacy and safety of CAMPATH-IH in MS patients.
  • To investigate the relationship between antibody treatment, cytokine release, and neurological symptom exacerbation in MS.
  • To explore potential interventions to mitigate adverse effects.

Main Methods:

  • Pilot study involving 14 patients with multiple sclerosis treated with CAMPATH-IH.
  • Four patients also received anti-CD4 antibody therapy.

Related Experiment Videos

  • Monitoring of disease activity via MRI, cytokine levels (TNF-α, IFN-γ, IL-6), and clinical symptoms.
  • Investigation of methylprednisolone pre-treatment effects.

    • Main Results:

    • CAMPATH-IH treatment led to a substantial reduction in MS disease activity on MRI.
    • Antibody infusions caused transient neurological symptom exacerbation in 12 patients, correlating with increased circulating cytokines (TNF-α, IFN-γ, IL-6).
    • Pre-treatment with methylprednisolone prevented symptom flares and cytokine release in two patients.

    Conclusions:

    • Soluble immune mediators, such as cytokines, may contribute to MS symptom production by affecting neural pathway conduction.
    • CAMPATH-IH shows potential for reducing MS disease activity.
    • Methylprednisolone may be a viable strategy to manage infusion-related adverse effects during MS immunotherapy.